Last reviewed 2026-05-26 · How we verify

Homodamon (HOMOCHLORCYCLIZINE)

Phase 2 active Small molecule ✓ Verified May 2026

Homodamon (generic name: HOMOCHLORCYCLIZINE) is a homochlorcyclizine drug. It is currently in Phase 2 development.

Homodamon works by interacting with a specific target in the body, although the exact mechanism is currently unknown.

Homodamon is a small molecule with synonyms including CUROSAJIN, HOMOCHLORCYCLIZINE, and others. Its exact mechanism and indications are not specified in the provided information.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HOMOCHLORCYCLIZINE
Drug class	homochlorcyclizine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Homodamon is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. More research is needed to understand how Homodamon interacts with cells and what effects it has on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Homodamon CI brief — competitive landscape report
Homodamon updates RSS · CI watch RSS

Frequently asked questions about Homodamon

What is Homodamon?

Homodamon (HOMOCHLORCYCLIZINE) is a homochlorcyclizine drug.

How does Homodamon work?

Homodamon works by interacting with a specific target in the body, although the exact mechanism is currently unknown.

What is the generic name of Homodamon?

HOMOCHLORCYCLIZINE is the generic (nonproprietary) name of Homodamon.

What drug class is Homodamon in?

Homodamon belongs to the homochlorcyclizine class. See all homochlorcyclizine drugs at /class/homochlorcyclizine.

What development phase is Homodamon in?

Homodamon is in Phase 2.

Drug class: All homochlorcyclizine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing